Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05294965
Other study ID # EKNZ 2022-00037
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date April 27, 2022
Est. completion date March 6, 2023

Study information

Verified date September 2023
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to asses brown adipose tissue activity in humans after intravenous administration of the selective beta-2-adrenergic agonist fenoterol as compared to the natural activator of brown adipose tissue, a mild cold stimulus.


Description:

The activation of brown adipose tissue in response to beta-2-adrenergic stimulation as compared to cold exposure will be studied in an open-label, cross-over trial in healthy volunteers with random sequence of the two study interventions a) and b): 1. A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose of fenoterol per subject will thus be 145µg. 2. During 120 minutes participants will be exposed to a mild cold stimulus water using cooling sleeves, covering the participant's waist, is gradually decrease body surface temperature to 10 degrees or to the lowest tolerable temperature without shivering. Energy expenditure will be measured during both interventions by indirect calorimetry and brown adipose tissue activity will determined by 18F-FDG-PET/CT 30 min after injection of 75 MBq of 18F-FDG.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date March 6, 2023
Est. primary completion date March 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - BMI 18,5-23 kg/m2 or 30-35 kg/m2 Exclusion Criteria: - History or signs of any medical or psychological condition - pregnancy or lactation - medications except prescription free analgesics and contraceptives - habitual alcohol or tobacco use - weight change >5% within prior 3 months - Resting heart rate >85 bpm - Systolic blood pressure >140 mmHg or diastolic blood pressure <50 mmHg - Presence of following ECG changes: ST-segment deviations, QTc >500ms, signs of pre-excitation - Hyper- or Hypothyroidism - inability to follow study procedures - Enrolment of the investigator, his/her family members, employees and other dependent persons - hypersensitivity to cold - enrolment into study with ionizing radiation within prior 12 months. - Cold induced thermogenesis of less than 5% basal metabolic rate and normal weight or cold induced thermogenesis of more than 5% and overweight (determined during screening visit)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fenoterol
Intravenous infusion
Other:
Mild cold exposure
Body surface cooling

Locations

Country Name City State
Switzerland University Hospital Basel, Dept. of Endocrinology Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary BAT SUVmean 18F-FDG uptake into the supra-clavicular brown adipose tissue as determined by 18F-FDG PET-CT after the respective study intervention 30 minutes after end of intervention
Secondary BAT SUVmax maximum SUV in supraclavicular adipose tissue (according to BARCIST 1.0) 30 minutes after intervention
Secondary BAT Volume volume of supraclavicular adipose tissue (according to BARCIST 1.0) 30 minutes after intervention
Secondary BAT glycolytic volume volume of supraclavicular adipose tissue x SUVmean (according to BARCIST 1.0) 30 minutes after intervention
Secondary Change in energy expenditure Quantitative change in EE above resting metabolic rate in response to the respective study intervention. Measured by indirect calorimetry. First and last 30 minutes of intervention
See also
  Status Clinical Trial Phase
Completed NCT04766021 - Mirabegron and Physiological Function in Cold Environments Phase 1/Phase 2
Completed NCT01898949 - Stimulation of Diet-Induced Thermogenesis by Cold-Exposure N/A
Completed NCT06121817 - Thermogenic Effect and Metabolic Responses of Durian N/A
Completed NCT05990387 - MIrabegron and Physiological Function in Cold Environments Phase 1/Phase 2